Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$3.8M | 2 yrs ago

About Opal Biosciences

Opal is an Australian biotechnology company committed to tackling infectious diseases.

Opal Biosciences Headquarters Location

Level 4 100 Albert Road

South Melbourne, Victoria, 3205,


+ 61 3 9692 7240

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Opal Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Opal Biosciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Opal Biosciences News

BioDiem : Extension to Closing Date of Opal Capital Raising

Jun 12, 2021

06/12/2021 | 05:37am EDT Message : Level 4, Phone: +613 9692 7240 Extension to Closing Date of Opal Capital Raising Melbourne, 11 June 2021: Following the announcement by Australian infectious disease therapy company Opal Biosciences Limited ("Opal") on 6 May 2021 in relation to its Information Memorandum to raise up to $5 million through the issue of 33,333,333 shares at $0.15 (15 cents) per share, Opal today announces that the Offer closing date under the Information Memorandum will be extended by one (1) month from 15 June 2021 to 5.00pm (Melbourne time) on 15 July 2021. The updated indicative timetable is outlined below: IMPORTANT DATES Issue date and despatch of share certificates for New Shares 20 July 2021 Note: The timetable above is indicative only and may be subject to change. The proceeds from the Capital Raising will be used to fund the transaction costs associated with the acquisition of revenue-generating specialist pharmaceutical formulation developer, Formulytica Pty Ltd, fund the growth of Formulytica's contract and innovative business, build a small batch sterile manufacture/GMP facility and provide Opal with general working capital to continue with the development and operation of Opal's business. The Formulytica acquisition will be effective on the completion of the capital raising and Formulytica's Peter Cox and Dr Richard Buchta will then join the Opal Board. The Offer under the Information Memorandum is subject to a minimum subscription amount of $2,000,000. If the minimum subscription amount is not reached, any application money received by Opal will be returned in full (without interest) to Applicants. The Offer of shares pursuant to this Information Memorandum is only available to investors to whom an offer can be made without the need for a Disclosure Document to be provided under the Corporations Act 2001 (Cth). The Information Memorandum is not a prospectus or product disclosure document under the Corporations Act and has not been lodged with ASIC. The attention of potential investors is drawn to the Important Notices on page 2 of the Information Memorandum. Application Forms can be obtained by contacting the office on (03) 9692 7240 or email: - ENDS - About Opal Biosciences Ltd Opal Biosciences is a preclinical stage Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. For more information, please visit About Formulytica Pty Ltd Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica's services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica's injectable parenteral expertise covers solution and lipid based formulations, in biologics, as well as small organic molecules. For more information, please visit Further information

  • When was Opal Biosciences founded?

    Opal Biosciences was founded in 2020.

  • Where is Opal Biosciences's headquarters?

    Opal Biosciences's headquarters is located at Level 4, South Melbourne.

  • What is Opal Biosciences's latest funding round?

    Opal Biosciences's latest funding round is Unattributed VC.

  • How much did Opal Biosciences raise?

    Opal Biosciences raised a total of $3.8M.

  • Who are the investors of Opal Biosciences?

    Investors of Opal Biosciences include Apple Tree Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.